Comparison
3 Methylglutaconic Aciduria Type 2 C0574083 vs 17q11 2 Microduplication Syndrome C3495679
Clinical comparison between 3 Methylglutaconic Aciduria Type 2 and 17q11 2 Microduplication Syndrome for differential diagnosis and treatment planning.
3 Methylglutaconic Aciduria Type 2 C0574083
Also called Barth syndrome, this genetic condition primarily affects males and impairs mitochondrial function. It causes heart muscle weakness, muscle weakness, and recurrent infections. Treatment includes cardiac care, infection prevention, and supportive therapies.
17q11 2 Microduplication Syndrome C3495679
A genetic disorder caused by duplication of a segment on chromosome 17. Individuals may have developmental delays, behavioral concerns, and physical features. Treatment focuses on early intervention.
6 comparison axes
Onset
3 Methylglutaconic Aciduria Type 2 C0574083
0-5
17q11 2 Microduplication Syndrome C3495679
0-null
Onset patterns differ
Severity
3 Methylglutaconic Aciduria Type 2 C0574083
severe
17q11 2 Microduplication Syndrome C3495679
moderate
Different severity levels
Chronic
3 Methylglutaconic Aciduria Type 2 C0574083
Chronic
17q11 2 Microduplication Syndrome C3495679
Chronic
Differing course
Communicable
3 Methylglutaconic Aciduria Type 2 C0574083
No
17q11 2 Microduplication Syndrome C3495679
No
Different transmission
Body System
3 Methylglutaconic Aciduria Type 2 C0574083
metabolic
17q11 2 Microduplication Syndrome C3495679
congenital
Same/different system
Category
3 Methylglutaconic Aciduria Type 2 C0574083
metabolic
17q11 2 Microduplication Syndrome C3495679
genetic
Different category
Bottom line
3-methylglutaconic-aciduria-type-2-C0574083 and 17q11-2-microduplication-syndrome-C3495679 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Methylglutaconic Aciduria Type 2 C0574083 | 17q11 2 Microduplication Syndrome C3495679 | Discriminating power |
|---|---|---|---|
| Heart muscle weakness | Cardiomyopathy is a recognized core feature and may be severe. | Not described as a typical feature in the supplied source. | High |
| Developmental and behavioral concerns | Not the defining presentation in the supplied description. | Developmental delay and behavioral concerns are reported features. | High |
| Recurrent infections | Recurrent infections are a recognized feature. | Not established by the supplied source. | Moderate |
When to favor each condition
Choose 3 Methylglutaconic Aciduria Type 2 C0574083 when
Male infant or child with cardiomyopathy and muscle weakness
This pattern matches the described mitochondrial presentation of Barth syndrome.
High
Recurrent infections with suspected metabolic disease
Infection susceptibility is specifically described for the left condition.
Moderate
Abnormal organic-acid result needing diagnosis
An abnormal result is not itself a diagnosis and requires specialist confirmation.
High
Choose 17q11 2 Microduplication Syndrome C3495679 when
Developmental delay with behavioral concerns
These are the main features described for the microduplication.
Moderate
Congenital presentation without dominant cardiac disease
The source emphasizes developmental and physical features rather than cardiomyopathy.
Moderate
Suspected chromosomal copy-number change
The condition is defined by duplication of a chromosome 17 segment.
High
How key tests differ
| Test | 3 Methylglutaconic Aciduria Type 2 C0574083 | 17q11 2 Microduplication Syndrome C3495679 | Interpretation |
|---|---|---|---|
| Urine organic acids | May suggest 3-methylglutaconic aciduria; cutoff values are not supplied. | No characteristic organic-acid pattern is established here. | An abnormal result supports evaluation but does not alone confirm Barth syndrome. |
| Chromosomal microarray | Not the defining test in the supplied description. | May identify a 17q11.2 duplication. | A detected duplication requires clinical correlation and clinician interpretation. |
| Cardiac evaluation | May show heart-muscle weakness or cardiomyopathy. | No expected cardiac abnormality is established by the source. | Cardiac findings help assess severity but should be interpreted clinically. |
Prognosis comparison
3 Methylglutaconic Aciduria Type 2 C0574083
- Outcome
- Often severe and chronic, with cardiac, muscle, and infection-related risks; exact outcomes vary.
- Factors
- Heart function, infection burden, muscle weakness, and access to specialist care.
17q11 2 Microduplication Syndrome C3495679
- Outcome
- Generally described as moderate, but individual developmental and behavioral outcomes vary.
- Factors
- Extent of developmental delay, behavioral needs, associated features, and early support.
Time frame: Both are chronic; left onset is described in early childhood, while right onset timing is not precisely established.
Prognosis should be individualized; mortality and long-term rates are not supplied.
Complications comparison
| Complication | Presentation |
|---|---|
| Cardiac complications | Heart-muscle weakness may cause serious illness. Not established from the supplied description. Cardiac care is specifically mentioned for the left condition. |
| Infection | Recurrent infections are described. Infection risk is not established here. Prevention and prompt assessment are relevant for the left condition. |
| Developmental needs | Not the main described complication. Developmental delay and behavioral concerns may require support. Early intervention is the stated focus for the right condition. |
Patient education highlights
- HighDifferent conditions
These are distinct genetic conditions and should not be treated as interchangeable.
- HighSpecialist follow-up
Cardiac, metabolic, genetic, developmental, and infection concerns need clinician-directed care.
- MediumTest meaning
An abnormal laboratory or genetic result is a finding, not automatically a complete diagnosis.